Therapy Finder Advisor
Director of the Thoracic Oncology Program
Professor, University of Chicago
Selumetinib, a MEK inhibitor developed by AstraZeneca, is an investigational therapy currently in clinical trials for non-small cell lung cancer (NSCLC) and several other cancer types. Recent results from a phase 2 clinical trial (NCT00890825) have demonstrated that selumetinib given in combination with docetaxel has "promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC" (Janne PA, et al. 2013). This is the first prospective study to demonstrate clinical benefit of a targeted therapy for KRAS mutation-positive NSCLC patients.
Selumetinib targets the mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) that function downstream of RAS.
Side effects associated with selumetinib have been reported as mild, and the toxicity profile is favorable in comparison to other targeted agents and chemotherapies. The most common side effects are rash, fatigue, diarrhea, and peripheral edema. Only 16% of patients discontinued selumetinib therapy due to adverse events.
Selumetinib is not yet approved by the FDA. It is currently in clinical trials for various cancer types including NSCLC, thyroid cancer, melanoma, pancreatic cancer, lymphoma, colorectal cancer and others. Your patient could access this drug by enrolling in a clinical trial.
|Selumetinib||MAP2K1, MAP2K2||Array BioPharma||Investigational|
Dear Therapy Finder® User:
During the past two years we have witnessed an unprecedented upswing in research activity leading to the identification of increasing numbers of actionable biomarkers and several effective targeted treatments. To accommodate this dramatic increase in the number of relevant biomarkers, their interactions, and other patient attributes, we are developing a new application design, one that will be both easier to use and more relevant to practicing physicians and patients. This new system will unify many of the best features and key learnings from the Therapy Finders with those from our Genomic Variant Annotation™ (GVA) reporting system.
Until we complete the redesign of our Therapy Finders or offer substitute decision-support products, we are suspending the updating of the Therapy Finders appearing on the CollabRx website and other sites.
If you click through and decide to use the Colon Cancer, Lung Cancer, Melanoma or Metastatic Breast Cancer Therapy Finders, please do so with caution, as some of the data have not been updated since October 15, 2014.
July 6, 2015